King Pharmaceuticals

This page shows the latest King Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

FDA panel backs Pfizer and Teva abuse-resistant painkillers

The company secured rights to Troxyca ER (also known as ALO-02) when it acquired King Pharmaceuticals in 2010 for $3.6bn.

Opioid analgesics

The initial development of this immediate-release tamper-resistant formulation, formally known as Acurox, was under collaboration with Acura and King Pharmaceuticals. ... As part of the research programme initiated by King Pharmaceuticals (now Pfizer)
Burton Paul appointed to 1HQ’s health division

Paul brings more than 15 years experience in managing projects and clients across a wide range of sectors including FMCG and pharmaceuticals. ... His work includes brand delivery for some of the biggest names in the sector, most notably: Adcock Ingram,
Lipitor losses affect Pfizer's Q2 sales

Sales were aided by the purchase of King Pharmaceuticals, with Pfizer gaining an extra $357m in sales.
FDA approves Pfizer's pain drug

Oxecta was originally developed by King Pharmaceuticals. Pfizer acquired the drug when it purchased King in late 2010.
Survival strategy

Marketed products. The M&A strategy in 2010 was reflected in Pfizer's acquisition of King Pharmaceuticals for $3.6bn announced in October and Astellas' acquisition of OSI Pharmaceuticals for $4bn ... Nevertheless there were a few deals in 2010, such as

More from news
Approximately 0 fully matching, plus 21 partially matching documents found.

GW hires Pfizer’s Kenneth Sommerville

Dr Sommerville was VP, clinical sciences, at Pfizer for three years having joined the company from King Pharmaceuticals.
ParagonRx appoints ex-FDA medical officer

He was promoted to senior director of medical affairs and then after King Pharmaceuticals' acquisition of Alpharma, Dr Sun served as King's senior director of pharmacovigilance and risk management.